Eric Jonasch
MD
Professor, Department of Genitourinary Medical Oncology
👥Biography 个人简介
Eric Jonasch is a leading expert in VHL disease and hereditary renal cell carcinoma syndromes. He was principal investigator on the landmark LITESPARK-001 trial establishing belzutifan for VHL disease-associated tumors including RCC, hemangioblastomas, and pancreatic neuroendocrine tumors, leading to the first FDA approval for VHL disease. His work bridges the molecular biology of the VHL-HIF pathway to clinical drug development.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Eric Jonasch 的研究动态
Follow Eric Jonasch's research updates
留下邮箱，当我们发布与 Eric Jonasch（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment